18F-PSMA-1007

Radiopharmaceuticals, which combine radioactive isotopes with specific molecular carriers, are ushering in a new era of personalized medicine. These specialized drugs precisely target diseased tissues within the human body and release ionizing radiation for diagnostic or therapeutic purposes, significantly enhancing the accuracy and effectiveness of disease management. From traditional thyroid function tests to their current widespread application in cancer, cardiovascular diseases, and neurodegenerative disorders, the development of radiopharmaceuticals reflects how advancements in science and technology are driving innovation in medicine. With the advent of cutting-edge technologies such as radioligand therapies (RDCs), radiopharmaceuticals are not only improving the accuracy of tumor diagnostics but also offering new treatment options for previously intractable diseases. Notably, innovative drugs such as 177Lu-PSMA-617 and 18F-PSMA-1007 are leading the way in precision medicine for malignancies like prostate cancer and renal cell carcinoma. Mechanism of Action of RadiopharmaceuticalsRadiopharmaceuticals, also known as radioactive drugs or radionuclide formulations, are specialized agents that utilize radioactive isotopes bound to specific molecular carriers for medical diagnosis and treatment. These compounds can selectively target specific areas of the body—such as tumors or other diseased tissues—and emit ionizing radiation to fulfill their intended function. Over the past decades, the application of radiopharmaceuticals has expanded from traditional thyroid diagnostics to the treatment and imaging of cancer, cardiovascular conditions, and neurodegenerative diseases. With technological progress, especially in radioligand therapy, radiopharmaceuticals can act more precisely on target cells while minimizing damage to surrounding healthy tissues. The introduction of alpha-particle emitters has brought new hope to therapy, thanks to their higher cytotoxicity and shorter range, making them especially suitable for hard-to-treat tumors. Mechanism of Action of RDC Drugs1The mechanism by which radiopharmaceuticals function in cancer treatment relies on the ionizing radiation emitted by radioactive isotopes. This radiation damages the DNA of cancer cells, inhibiting their division and proliferation. Different isotopes emit various types of radiation, such as beta particles or alpha particles, each affecting cancer cells differently. Beta particles, which have moderate penetration ability, can affect cancer cells several cell diameters away, creating a "crossfire effect" that extends the therapeutic range. In contrast, alpha particles possess extremely high energy density and short range, enabling them to inflict severe damage within a limited area—often requiring only a few alpha particles to pass through a cancer cell nucleus to achieve cytotoxicity. One of the key advantages of radiopharmaceuticals lies in their high specificity and low systemic toxicity. By conjugating radioactive isotopes to targeting ligands—such as antibodies or specific peptides—the isotopes can accumulate selectively in tumor sites, substantially increasing the local radiation dose while minimizing exposure to healthy tissue. This strategy not only improves therapeutic efficacy but also reduces the incidence of side effects. In addition, some radiopharmaceuticals can also serve diagnostic purposes, allowing physicians to monitor disease progression in real time during treatment—thus achieving a theranostic (therapy + diagnostic) approach. Another benefit is their low likelihood of inducing drug resistance. Because their mechanism of action differs from that of conventional chemotherapeutics, cancer cells have a harder time developing resistance. Therefore, radiopharmaceuticals can be used as standalone therapies or in combination with other modalities, such as immunotherapy, to enhance overall treatment outcomes. Radioligand therapy (RLT), also known as radioimmunotherapy or radionuclide-conjugated drug therapy, involves binding a radioactive isotope to a molecule that targets specific cancer cells. This approach uses the emitted particles from radioactive substances to damage cancer cell DNA, thereby halting their growth and division. RLT plays a pivotal role in precision medicine, offering highly selective treatment of tumors while minimizing collateral damage to healthy tissues. The core of RLT lies in the use of radioligands—compounds composed of four key elements: a targeting moiety (e.g., antibody, peptide, or small molecule), a linker, a chelator, and a radioactive isotope. Once administered, these radioligands seek out and bind to overexpressed biomarkers on cancer cell surfaces. Upon binding, the isotope emits radiation that directly damages the cancer cell’s DNA, leading to cell death. Additionally, the so-called “bystander effect”—in which ionization of nearby water molecules produces free radicals—can also contribute to the destruction of adjacent cancer cells. Application of Radiopharmaceuticals in Cancer Treatment1）177Lu-PSMA-617 177Lu-PSMA-617 is an innovative targeted radioligand therapy specifically designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This therapy achieves high selectivity and precision in targeting prostate cancer cells by combining Lutetium-177—a radioactive isotope that emits beta particles—with a small-molecule compound that specifically binds to prostate-specific membrane antigen (PSMA). Schematic overview of the structure of a PSMA receptor1177Lu-PSMA-617 circulates in the bloodstream, identifying and binding to prostate cancer cells that overexpress PSMA. PSMA is highly expressed on the surface of prostate cancer cells and their metastases, while its expression in normal tissues is minimal. This allows the drug to effectively target cancer cells while sparing most healthy tissues. Once bound to PSMA on the surface of cancer cells, 177Lu-PSMA-617 is internalized. Inside the cell, Lutetium-177 emits beta particles that cause DNA damage, impairing the cancer cell's ability to replicate or inducing cell death directly. Although these beta particles are potent enough to destroy cancer cells, their limited penetration range—typically just a few millimeters—means that surrounding healthy tissues are largely unaffected. This reduces systemic side effects and enhances the safety profile of the treatment. The VISION study demonstrated that 177Lu-PSMA-617 in combination with the best standard of care (SOC) provides significant benefits over SOC alone in terms of prolonging overall survival (OS) and radiographic progression-free survival (rPFS). Specifically, patients treated with 177Lu-PSMA-617 showed higher overall survival rates and longer progression-free periods, along with improved objective response rates and disease control rates. Despite its high specificity and efficacy, 177Lu-PSMA-617 is not without side effects. For instance, salivary gland dysfunction may occur due to off-target uptake, as salivary glands also express PSMA. Therefore, during clinical application, physicians must closely monitor patients and take appropriate measures to manage and mitigate potential adverse effects. 2) 177Lu-Rosopatamab Tetraxetan TLX591 (177Lu-Rosopatamab Tetraxetan) is another radiolabeled compound that targets prostate-specific membrane antigen (PSMA). It couples the radioactive isotope 177Lutetium with the monoclonal antibody rosopatamab tetraxetan. Rosopatamab tetraxetan specifically recognizes and binds to PSMA, which is overexpressed on the surface of prostate cancer cells. 177Lutetium serves as a beta particle emitter, delivering cytotoxic radiation that damages the DNA of cancer cells. Upon administration, rosopatamab tetraxetan seeks out and attaches to PSMA-positive prostate cancer cells, enabling 177Lutetium to emit beta radiation with sufficient energy to destroy nearby tumor cells while limiting damage to distant healthy tissue, thus preserving normal function. Multiple completed Phase I and II clinical trials have shown that TLX591 has a favorable safety and efficacy profile, and have validated the effectiveness of optimized fractionated dosing regimens. The ProstACT SELECT study demonstrated that, in patients with progressive mCRPC who had already undergone treatment, the median radiographic progression-free survival (rPFS) following TLX591 therapy was 8.8 months, indicating significant clinical benefit. Moreover, TLX591 is currently being evaluated in a Phase III international, multicenter, randomized controlled trial named ProstACT GLOBAL—the first such study targeting PSMA-positive mCRPC patients—to further assess its efficacy and safety compared to standard-of-care therapies. Grand Pharmaceutical has acquired the rights to develop and commercialize TLX591 in the Chinese market through a collaboration with Telix Pharmaceuticals. This strategic partnership not only facilitates the introduction of innovative therapies in China but also enhances the company’s global R&D and manufacturing capabilities, supporting the advancement of cutting-edge cancer diagnosis and treatment solutions. With TLX591's promising performance in the international market and its progressing rollout in China, it is expected to offer a new therapeutic option for prostate cancer patients in the coming years. Application of Radiopharmaceuticals in Early Tumor Diagnosis1) 18F-PSMA-1007 18F-PSMA-1007 is a positron emission tomography (PET) imaging agent specifically used for the diagnosis and staging of prostate cancer. This radiotracer targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer cells, particularly in cases of recurrence or metastasis. By labeling a small-molecule PSMA inhibitor with the radioisotope fluorine-18 (18F), 18F-PSMA-1007 enables highly sensitive and specific detection of prostate cancer lesions. 18F-PSMA-1007 PET/CT (arrow) staining of the PSMA-positive primary tumor2For patients who experience a rise in serum PSA levels after radical prostatectomy, recurrence is often suspected. However, traditional imaging techniques frequently fail to precisely localize recurrent lesions. 18F-PSMA-1007 PET/CT has demonstrated significant advantages in detecting small lesions in such patients due to its high sensitivity and specificity, enabling earlier detection of recurrence and timely adjustment of therapeutic strategies. In patients with PSA levels in the “gray zone” (i.e., between 4 and 10 ng/mL), determining the presence of prostate cancer poses a diagnostic challenge. 18F-PSMA-1007 PET/CT, when combined with PSA-derived indicators such as PSA density (PSAD), can improve diagnostic accuracy in this group and reduce the number of unnecessary biopsies. This approach not only helps avoid overdiagnosis and overtreatment but also provides more precise therapeutic guidance for patients who do have prostate cancer. 18F-PSMA PET/CT for primary staging showed high PSMA uptake in the prostate gland2By leveraging radiomics models based on 18F-PSMA-1007 PET/CT, researchers can extract numerous features from PET images and analyze them using machine learning algorithms to effectively distinguish prostate cancer from benign prostatic hyperplasia (BPH). This enhances diagnostic accuracy and contributes to more evidence-based clinical decision-making. Studies also suggest that 18F-PSMA-1007 PET/CT can be used to predict the pathological grade of prostate cancer, which is critical for prognosis assessment. This imaging technique provides important insights into tumor biology, enabling the formulation of personalized treatment plans. Compared to conventional 18F-FDG PET/CT, 18F-PSMA-1007 PET/CT offers higher sensitivity and specificity in detecting bone metastases from prostate cancer. This improves the detection of distant metastases, which is particularly important in managing advanced prostate cancer. Moreover, for suspected metastatic cases, the combined use of 18F-FDG and 18F-PSMA-1007 PET/CT can further enhance staging accuracy and guide clinical treatment decisions. 2) TLX250-CDx (89Zr-TLX250) TLX250-CDx (89Zr-TLX250) is a radiopharmaceutical diagnostic conjugate (RDC) that targets carbonic anhydrase IX (CA9) and is specifically designed for the diagnosis of clear cell renal cell carcinoma (ccRCC). Zirconium-89 (89Zr) is a positron-emitting isotope with a physical half-life of approximately 78.4 hours, making it well-suited for use with monoclonal antibodies due to its alignment with the biological distribution timeline of antibodies in the body. This allows 89Zr-labeled antibodies to achieve optimal tumor accumulation, thereby improving imaging sensitivity and specificity. The anti-CA9 antibody used in TLX250-CDx binds selectively to the CA9 protein, which is overexpressed on the surface of cancer cells. CA9 expression is minimal in normal tissues but significantly elevated in various cancers, especially ccRCC, making it an ideal diagnostic target. Scheme of the bioconjugation and radiolabeling of 89Zr-TLX2504Once injected into the patient, TLX250-CDx circulates through the bloodstream and accumulates at tumor sites due to its high affinity for CA9. Using PET imaging, detailed in vivo images can then be generated, revealing the tumor’s location, size, and potential metastasis. This method not only improves diagnostic accuracy but also avoids the risks associated with invasive procedures such as biopsies. In the pivotal Phase III ZIRCON clinical trial, TLX250-CDx demonstrated outstanding performance. For patients suspected of having ccRCC but not yet diagnosed, the agent achieved a sensitivity of 86% and specificity of 87% in diagnosing ccRCC, with a positive predictive value (PPV) of 93%. These results suggest that TLX250-CDx could become a vital non-invasive diagnostic tool, enabling more precise clinical decision-making. In addition to ccRCC, ongoing research is exploring the utility of TLX250-CDx in other CA9-expressing cancers, such as bladder cancer and urothelial carcinoma. These cross-indication studies could expand the market potential of TLX250-CDx and provide effective diagnostic solutions for a broader range of cancers. ZIRCON is a global Phase III clinical trial designed to evaluate the efficacy and safety of TLX250-CDx in diagnosing ccRCC. The results have been encouraging: for patients with renal masses identified by CT or MRI but not definitively diagnosed as ccRCC, TLX250-CDx PET imaging showed 86% sensitivity and 87% specificity, with a PPV of 93%. These figures far exceed the U.S. FDA’s predefined thresholds (sensitivity and specificity ≥70%), indicating that TLX250-CDx has strong potential to become a new clinical diagnostic standard for ccRCC. Beyond its diagnostic role in ccRCC, TLX250-CDx has shown promise in other cancer types. Studies are underway to assess its use in triple-negative breast cancer (TNBC), non-muscle-invasive bladder cancer (NMIBC), and urothelial carcinoma. If approved, TLX250-CDx would become the first commercially available imaging agent for ccRCC, addressing a significant unmet need. Given the often asymptomatic nature of early-stage kidney cancer, many patients are diagnosed at an advanced stage. Therefore, the early diagnostic capabilities provided by TLX250-CDx could substantially improve treatment outcomes and quality of life. ConclusionRadiopharmaceuticals offer tremendous potential in the diagnosis and treatment of cancer and other diseases due to their high selectivity and low systemic toxicity. They enhance diagnostic accuracy and enable earlier detection, while also providing safer and more effective therapeutic options for patients. For instance, 177Lu-PSMA-617 and TLX591 target prostate-specific membrane antigen (PSMA), bringing new hope to patients with metastatic castration-resistant prostate cancer (mCRPC); while 18F-PSMA-1007 and TLX250-CDx have shown remarkable success in the early diagnosis of prostate cancer and clear cell renal cell carcinoma (ccRCC), respectively. Furthermore, the use of these agents supports the development of theranostics—combining diagnosis and treatment—allowing clinicians to monitor disease progression in real-time and tailor treatment strategies to individual patient needs. How to obtain the latest research advancements in the field of biopharmaceuticals? In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery! Reference 1.Chiliveri SC, Robertson AJ, Shen Y, Torchia DA, Bax A. Advances in NMR Spectroscopy of Weakly Aligned Biomolecular Systems. Chem Rev. 2022 May 25;122(10):9307-9330. doi: 10.1021/acs.chemrev.1c00730. Epub 2021 Nov 12. PMID: 34766756.2.van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H. Pharmacological Optimization of PSMA-Based Radioligand Therapy. Biomedicines. 2022 Nov 23;10(12):3020. doi: 10.3390/biomedicines10123020. PMID: 36551776; PMCID: PMC9775864.3.Jochumsen MR, Bouchelouche K. PSMA PET/CT for Primary Staging of Prostate Cancer - An Updated Overview. Semin Nucl Med. 2024 Jan;54(1):39-45. doi: 10.1053/j.semnuclmed.2023.07.001. Epub 2023 Jul 22. PMID: 37487824.4.Yoon JK, Park BN, Ryu EK, An YS, Lee SJ. Current Perspectives on 89Zr-PET Imaging. Int J Mol Sci. 2020 Jun 17;21(12):4309. doi: 10.3390/ijms21124309. PMID: 32560337; PMCID: PMC7352467.

关于Tadashi Watabe教授 Tadashi Watabe是大阪大学放射科教授，也是国际上使用砹（At-211）进行靶向阿尔法治疗的领军人物之一，特别是在At-211的临床转化方面作出了重大贡献。目前，他在大阪大学医院主持Alpha-T1试验（NCT05275946），利用砹（[211At]NaAt）治疗对放射性碘治疗无效的甲状腺癌患者。此外， Watabe博士已于2024年启动另一项使用[211At]PSMA-5靶向前列腺特异性膜抗原（PSMA）的临床试验（NCT06441994），用于治疗去势抵抗性前列腺癌患者。除此之外, Watabe博士还负责多项关于[18F]FAPI-74（NCT05442151）和[18F]PSMA-1007的临床研究。 关于Oncidium基金 Oncidium Foundation 是全球核药领域规模最大、知名度最高的公益基金会。作为一个非营利组织，它致力于推动核药的研究、开发和应用。Oncidium Foundation 在全球拥有超过 100 位大使，这些大使在各自领域积极推动核药技术的普及与发展，为全球健康事业贡献力量。该基金会由核药领域的权威人物Richard Zimmermann博士创立。Richard Zimmermann博士共参与创办6家核素药企企，负责建立了欧洲PET/FDG供应网络，并担任核素药巨头Telix的董事和特别顾问。Richard博士同时担任IBA Molecular的业务发展副总裁，主导了IBA所有产品管线的搭建。 Cristiana Gameiro是IBA的资深专家（Fellow）及高管，负责领导核化学与核药物开发领域的工作。同时，她还担任欧盟药监局（EMA）的核药顾问等重要社会职务，在核药领域具有丰富的专业经验和广泛的影响力。 在这次采访中，Watabe教授与Oncidium Foundation的科学顾问Cristiana Gameiro博士深入探讨了At-211在α疗法中的进展、挑战及未来潜力，重点分析了其临床应用、生产优势以及对患者护理的深远影响。 采访内容  Q Cristiana Gameiro博士： Watabe博士，您能否简要介绍α疗法及其在改善患者预后方面的意义和重要性？尤其是相较于其他放射疗法，α疗法对患者有哪些独特优势？ Watabe教授： 首先，非常感谢您的邀请，让我有机会分享我们在砹靶向α疗法方面的研究进展。 α疗法目前仍处于早期发展阶段，全球范围内仅有一种获批药物：镭-223（Xofigo®），用于治疗去势抵抗性前列腺癌患者的骨转移。除此之外，锕-225、砹-211、铅-212等其他α放射性同位素也展现出广阔的医疗应用前景。α核素的优势在于其高能量传递能力，可高效诱导DNA双链断裂，从而在治疗效果上优于传统的X射线或β放射性配体疗法。 目前，我们正在开展两项临床试验：一项使用NaAt治疗甲状腺癌，另一项使用211At-PSMA-5治疗前列腺癌。此外，我们还在积极开发针对多种肿瘤的靶向At-211药物。希望在不久的将来，能够推动基于At-211的α核素药物获批，实现真正的临床突破。 A Q Cristiana Gameiro博士： At-211在患者治疗中有哪些特点，使其备受关注？ Watabe教授： 首先，α疗法面临的主要挑战之一是如何确保稳定的生产和供应。 At-211可以通过回旋加速器、采用天然铋作为靶材料进行生产。通过建立回旋加速器设施，我们能够大幅提升At-211的生产规模。与其他α核素相比，这是一个显著优势，因为At-211的供应无需依赖进口。例如，日本作为一个没有医疗反应堆的岛国，必须从国外进口治疗性放射性核素，如碘-131、镥-177或镭-223，而At-211可以通过回旋加速器在国内生产，从而提高供应的可及性及稳定性。 此外，砹作为卤素，与碘具有类似的化学性质，能够直接与碳或苯环结合，无需使用额外的螯合剂，这是药物开发的显著优势。在治疗诊断学（Theranostics）领域， At-211还可与氟或碘配对用于诊断成像，从而实现诊疗一体化，使其在α疗法中具有独特的应用潜力。 总体而言，α核素的主要优势在于其高能量转移能够高效诱导DNA双链断裂，从而显著提升疗效。 A Q Cristiana Gameiro博士： 关于研究和临床试验方面，您能否介绍一下目前关于砹的最新临床研究进展？ Watabe教授： 在大阪大学，我们正在开展两项由研究者发起的临床试验：一项是针对甲状腺癌的Alpha-T1试验，另一项是针对前列腺癌的Alpha-PS1试验。 Alpha-T1试验纳入了对碘-131治疗无效的患者。通常，这些患者已经接受了三次以上的放射性碘治疗，但病情仍有进展。在该试验中，砹化钠（211At[NaAt]）能够像碘一样在甲状腺癌细胞中积累，我们正在评估砹化钠（211At[NaAt]）的安全性和有效性。 目前，我们已经完成了11名患者的I期临床试验。虽然由于专利申请的原因，我无法透露详细结果，但可以透露的是，部分患者治疗效果良好。 Alpha-PS1试验是一种靶向PSMA的治疗诊断学方法。我们开发了一种新型化合物211At-PSMA-5，其诊断对应物是18F-PSMA-1007，两者具有非常相似的化学结构。 这是首次人体剂量递增研究，目前我们已进入第二个剂量组。我们已经为6名患者注射了211At-PSMA-5，他们对治疗的耐受性非常好。 去年12月，我们发表了211At-PSMA-5的首个人体PET图像，显示其在局部复发灶和转移性淋巴结中的积累非常高。这证明了211At-PSMA-5能够精准靶向表达PSMA的病变灶，其成像效果与18F-PSMA-1007 PET的观察结果高度一致。 尽管初步数据令人鼓舞，我们仍需要进一步积累临床数据，以全面验证211At-PSMA-5的安全性和疗效。 A Q Cristiana Gameiro博士： 您的研究并非孤立进行，例如，您与德国的Giesel教授有合作。请问是否有其他研究机构的合作对您的研究和临床转化起到了关键作用？ Watabe教授： 在大阪大学，我们与多个学院保持紧密合作。例如，我们与核物理研究中心密切合作，该中心配备多台回旋加速器，能够生产At-211及其他稀有放射性同位素，为我们的研究提供稳定的同位素供应。 此外，我们还与理学院展开深度合作，特别是在辐射化学和有机化学领域专家的支持下优化了放射性配体的标记工艺和稳定性研究。通过这些跨学科合作，我们能够高效整合整个研究流程—从同位素生产、化学标记、临床前评估，到最终的临床评估。 大阪大学为放射性核素研究和临床转化提供了优越的科研环境，迄今为止取得了非常显著的成果。 A Q Cristiana Gameiro博士： 日本政府对这项研究提供了哪些支持？ Watabe教授： 目前，日本政府目前通过医学研究开发机构（AMED）资助我们的临床试验。此外，我们还得到了大阪大学初创企业Alpha Fusion的支持。 同时，日本政府也在大力推动医疗用放射性核素的本土化生产，目前，重点关注Tc-99m、At-211和Ac-225同位素的国产化。 目前，我们仍然依赖学术机构的回旋加速器进行At-211生产，产能有限，难以满足大规模临床试验（如II期或III期）的需求。因此，扩大生产能力至关重要。 值得庆幸的是，我们正在大阪大学建设新的生产设施，并得到了日本政府的支持。目前，建筑主体已经完工，下一步将安装一台全新的回旋加速器，以提升At-211的生产能力，更好地支撑后续临床研究。 A Q Cristiana Gameiro博士： 感谢您强调政府在推动癌症治疗高科技项目中的重要作用。这样的宏伟目标需要多方利益相关者的支持，不仅需要小型生物技术公司、企业或学术界的参与，更离不开政府的大力支持。 最后，我想以一个积极的话题结束这次采访。您对At-211的研究充满热情，能否谈谈您对其在日本未来发展的展望？ Watabe教授： 我们十年前就开始了At-211的研究。起初，我对At-211的安全性和有效性持怀疑态度，因为α核素的疗效尚未被充分验证。然而，随着临床前研究的推进，我们发现它在疗效上显著优于传统的β疗法。 目前，我们已成功获得了政府资金支持，并做好了推进这两项临床试验的充分准备。我坚信，At-211治疗具有广阔的应用前景。在日本，患者在使用β治疗药物（如镥-177或碘-131）时通常需要隔离在专门的病房中，而α疗法则可以在门诊完成，极大地提升了患者的治疗便利性。此外，尽管At-211半衰期较短（7.2小时），在物流和供应链管理方面存在一定挑战，但其短半衰期也赋予了治疗更高的灵活性。我们可以采用分次给药的方式，根据患者需求精准调整剂量，实现更加个性化的治疗方案，在保障患者用药安全方面更有益。 另一大优势是，At-211的快速衰变意味着患者体内的放射性残留极少。通常在给药后1至2天内，患者体内几乎不再有放射性物质。这一特性不仅提高了患者的安全性，同时也降低了医疗机构工作人员（如护士和医院管理人员）在操作过程中的辐射暴露风险。考虑到辐射安全问题往往是临床应用中的一个重要顾虑，这一优势无疑为At-211的推广奠定了良好的基础。 A Q Cristiana Gameiro博士： 最后，结合您的研究背景，您希望Oncidium基金会提供什么样的支持？ Watabe教授： 我期望Oncidium基金会能够支持At-211靶向α疗法的推广。考虑到癌症的多样性，α疗法和放射性配体疗法的临床应用仍然有限。为了扩展其应用范围，我们需要更多的临床数据来验证其安全性和有效性。同时，我也希望Oncidium基金会在提升公众及医疗界对该疗法的认知方面发挥作用，因为At-211疗法有望成为一种安全且对患者友好的治疗选择。 A Cristiana Gameiro博士： Oncidium基金会的核心使命正是提升公众及患者对这些新兴疗法（包括基于At-211的α疗法）的认知，并推动相关的科普工作。 非常感谢您，Watabe教授。这次采访让我们收获良多。 关于砹尔法纽克莱 砹尔法纽克莱(Alpha Nuclide)是中国首家专注于阿尔法核素生产供应的平台型企业。自2020年成立以来, 砹尔法围绕着阿尔法核素砹-211以及其他诊疗一体化核素, 建立了从早研到临床生产完整的平台, 并且在核素生产和核素药GMP级大规模生产等方向引领全球创新突破。砹尔法即将建成的华东生产中心装有两台30兆伏的回旋加速器, 为国内首创, 并且在核素生产方面具有完整的自主知识产权。预计于2025年第二季度建成后, 将彻底改变国内阿尔法核素供应局面。 宁波R&D总部： 地址：宁波市前湾新区玉海东路136号    嘉兴同位素生产基地： 地址：嘉兴市海盐同位素产业园 电话：18902207829 邮箱: weibin.zhuo@astathera.com 官网：www.astathera.com